Our Research




Tobacco Use among People Living with HIV

We are studying the mechanisms and outcomes of tobacco use among PWH to help more people quit smoking and improve clinical outcomes.

Cannabis for Symptom Management

We aim to understand how and why patients with medical conditions are using cannabis to manage symptoms such as pain and anxiety and how impacts other factors, like opioid use.

Community Engagement and Outreach

We believe building meaningful community partnerships and collaborating with communities is an essential part of the research we conduct and clinical training we provide.

End of Life Communication & Grief Support

The goal of this work is to help patients talk with their families and providers about what matters most at the end-of-life and to provide bereavement support.

read more


The Effect of Cannabis During Immune Checkpoint Inhibitors (ICI) Cancer Treatment

We aim to advance the science regarding the longitudinal benefits and harms of cannabis use among those treated with immunotherapy for cancer.

Read more


Mind to Quit

The goal of the Mind to Quit project is to test the tailoring of a smoking cessation app for people with Serious Mental Illness vs the use of brief smoking cessation advice.

Cannabis for Cancer

The Cannabis for Cancer project will describe cannabis use over time among individuals with cancer to A) assess changes in key patient related outcomes and opioid use and B) determine if cannabis use moderates the association between race and pain severity.


The goal of the MedCanna study is to develop a mobile health app that provides medical cannabis education and test whether this information helps improve key patient reported outcomes.



The IMPACT-C project will explore the benefits and harms of cannabis use for people undergoing immunotherapy for cancer by A) assessing the effects of cannabis use over 12 months, B) highlighting any connections between the effects and measure of neighborhood disadvantage, and C) noting any association with disease response, clinical outcomes and key immunological markers over 12 months.



In addition to collaborators across UB, Dr. Ashare and the ENABLE lab collaborate with investigators around the country: